ArticleBJUI compass2026
LUMBER: A feasible MRI-based 3D printed mould platform for ex vivo sampling of prostate cancer.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurate, reliable means to obtain fresh viable clinically localised prostate cancer tissue do not exist. We developed a method in which bespoke 3D-printed moulds can be created for any prostate and allow for ex vivo sampling of magnetic resonance imaging (MRI)-visible, biopsy-proven cancer lesions. We sought to demonstrate the ability of our platform to obtain fresh viable prostate cancer tissue after robot-assisted radical prostatectomy (RARP). Methods: Inclusion criteria were a patient that underwent MR-fusion biopsy (UroNav, Philips) with a resulting biopsy proven Gleason Grade (GG) ≥ 2 target. STL files for prostate boundary and target regions of interest (ROI), created as part of fusion biopsy, were exported from the UroNav and imported into SolidWorks (Dassault), a solid modelling computer-aided design and engineering application. A macro within SolidWorks was then applied to create a material-optimised mould around the prostate with needle guides to allow for targeted sampling. The 3D mould was exported as an STL file and then 3D-printed on a Stratasys Fortus 250 MC 3D Printer. During RARP, the specimen is extracted, the seminal vesicles detached and the prostate is placed in the mould for biopsy. The biopsy cores are sent to pathology for analysis and compared to specimens from the initial biopsy. Results: Twelve patients with MRI-visible lesions and biopsy proven GGG ≥ 2 cancer underwent RARP. In 12 out of 12 patients, ex vivo biopsies performed with the 3D-printed mould yielded prostate tissue with cancer. Conclusions: Our 3D-printed mould platform allows for ex vivo sampling of MRI identified and previously biopsied prostate cancer at the time of RARP. The native, cancerous tissue may then be used to advance further research. The potential applications for a platform that can reliably sample living prostate cancer tissue are numerous, including the ability to advance future cancer research as well as other solid-organ malignancies with targetable lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.